Partnership research
Chimie Balard Cirimat Carnot Institute at European Utility Week in Paris
Carnot Institutes to the show of BtoB meetings for composite materials
Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur (Pasteur MS Carnot Institute) to explore the potential of new targeted strains
DEINOVE, a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, has announced that it will benefit from the Institut Pasteur's provision of biological resources for the research of new antimicrobial agents from original strains. The Institut Pasteur (Pasteur MS Carnot Institute), one of the most renowned worldwide players in the area of infectious disease research, will entrust a targeted selection of strains from their bacterial collection to DEINOVE.
International Industries Forum about Innovative Bio-Based Materials
Curie Cancer : the launch of biotechnology company Honing Biosciences
Curie Cancer Carnot Institute and Freenome announce a strategic collaboration in cell-free DNA analysis using machine learning technology
Curie Cancer Carnot Institute and Freenome announce a strategic collaboration to evaluate Freenome’s artificial intelligence (AI) genomics platform as a novel tool to predict patient response to immuno-oncology therapies by observing changes in circulating cell-free biomarkers.
CALYM again ISO9001 certified
The Carnot Insitute CALYM obtained the renewal of its ISO 9001 certification for the management and monitoring of its research activities and the coordination of its CeVi collection of lymphoma viable cells. Particularity of this year, the changeover to the 2015 version.
CALYM’S 3rd SCIENTIFIC & PARTNERING DAY
CALYM’s 3rd SCIENTIFIC & PARTNERING DAY, will take place next October 17, 2016 in Paris, Espace Van Gogh, 62, quai de la Rapée.
CALYM researchers and clinicians will be happy to present the new lymphoma R&D offering and highlight research results of the consortium, from new therapeutic targets identification to Phase III pivotal clinical trials and beyond.
IPSEN and CELGENE representatives will bring industry standpoint.